Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

Part of paid clinical trials in Huntsville, Alabama.

Sponsor
University of Louisville
Study ID
NCT00932438
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Colon Cancer With Metastases to the Liver

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LC beads loaded with Irinotecan — DEVICE
    Chemoembolization using LC beads loaded with 100mg Irinotecan
  • Oxaliplatin — DRUG
    Oxaliplatin 85 mg/sqm, IV infusion every two weeks
  • Leucovorin — DRUG
    Leucovorin 200 mg/sqm, IV infusion every two weeks
  • 5-Fluorouracil — DRUG
    5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
  • Bevacizumab — DRUG
    Bevacizumab 5 mg/kg given at the discretion of the treating physician

Study Details

This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in patients with colorectal cancer.

Key Dates

First listed
Jul 3, 2009
Start date
Jun 30, 2009
Status verified
Mar 2018
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
70 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: LC Beads loaded with Irinotecan and FOLFOX6
    Device: LC Beads loaded with 100mg Irinotecan Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
  • Active Comparator: FOLFOX6 and Bevacizumab
    Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician

Primary Outcome Measure

Tumor Response [ Time Frame: Months 2, 4 and 6 ]

Locations (9)

FacilityCityStateZIPSite coordinators
Clearview Cancer CenterHuntsvilleAlabama35805-
Radiology Associates of Sacramento/Sutter Cancer CenterSacramentoCalifornia95816-
Emory UniversityAtlantaGeorgia30322-
Northside Hospital/GA Cancer SpecialistsAtlantaGeorgia30342-
University of LouisvilleLouisvilleKentucky40202-
Hematology and Oncology Assoc. at BridgeportTupeloMississippi38801-
Washington University/Alvin J. Siteman Cancer CenterSt LouisMissouri63110-
Providence Portland Medical Center/Providence Cancer CenterPortlandOregon97213-
Froedtert Memorial Lutheran HospitalMilwaukeeWisconsin53226-

Find similar trials in Huntsville, AL